AIC
FPRX

Ameritas Investment Company’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Ameritas Investment Company’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,000
Closed -$9K – 1961
2018
Q4 		$9K Buy
+1,000
New +$11.9K ﹤0.01% 1098

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameritas Investment Company's FPRX Position: Q1 2019 in Review

Ameritas Investment Company sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2019, closing a stake of 1,000 shares — an estimated $9K sold.

Ameritas Investment Company first reported a position in FPRX in Q4 2018 and held it in 1 quarter. The position peaked at $9K in Q4 2018. 113 funds tracked by Wall St. Rank hold FPRX as of Q1 2019.

  • Ameritas Investment Company reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 1,000 Five Prime Therapeutics, Inc. shares in Q1 2019, an estimated $9K.
  • Ameritas Investment Company first reported a position in Five Prime Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Ameritas Investment Company's Five Prime Therapeutics, Inc. position peaked at $9K in Q4 2018.
  • 113 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.